|Bid||800,000.00 x 0|
|Ask||801,000.00 x 0|
|Day's Range||796,000.00 - 807,000.00|
|52 Week Range||352,000.00 - 863,000.00|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 20, 2021 - Jan 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||499,500.00|
Samsung Biologics (KRX: 207940.KS) officially began construction of its Plant 4 in Incheon, South Korea. Dubbed the "Super Plant," the new, multi-story 238,000-square-meter construction will be the world's largest biopharmaceutical manufacturing facility of its kind boasting 256,000 liters total manufacturing capacity.
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients.
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality (VR) technology to connect with clients around the world. The company's experiential platform won the Best Digital Campaign award for its ingenuity and creativity in the biopharma space during Digital Pharma Innovation Week.